Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 4, Issue 4, 2010, Pages 519-529

  Clifton, Ian J ^a   Peckham, Daniel G ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

airborne transmission; bioaerosol; Burkholderia cepacia complex; cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AEROSOL; AIRFLOW; BACTERIAL TRANSMISSION; BURKHOLDERIA CEPACIA COMPLEX; CROSS INFECTION; CYSTIC FIBROSIS; GENOTYPE; HUMAN; INFECTION CONTROL; MORBIDITY; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 77955016690     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.42     Document Type: Review

References (98)

1. Wainwright BJ, Scambler PJ, Schmidtke J et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 318(6044), 384-385 (1985).
2. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245(4922), 1059-1065 (1989). (Pubitemid 19231813)
3. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066-1073 (1989). (Pubitemid 19231814)
4. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922), 1073-1080 (1989). (Pubitemid 19231815)
5. Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr. Pulmonol. 35(4), 257-262 (2003).
6. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1(8433), 865 (1985).
7. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338(8769), 725-726 (1991).
8. Wiesemann HG, Steinkamp G, Ratjen F et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr. Pulmonol. 25(2), 88-92 (1998).
9. Gibson RL, Emerson J, McNamara S et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 167(6), 841-849 (2003).
10. Johansen HK , Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47(2), 109-111 (1992).
11. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15(2), 194-222 (2002).
12. Nixon GM, Armstrong DS, Carzino R et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J. Pediatr. 138(5), 699-704 (2001).
13. Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J. Pediatr. 122(6), 854-860 (1993).
14. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12(3), 158-161 (1992).
15. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am. J. Epidemiol. 143(10), 1007-1017 (1996).
16. Kosorok MR, Zeng L, West SE et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr. Pulmonol. 32(4), 277-287 (2001).
17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23(5), 330-335 (1997).
18. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116(5), 714-719 (1990).
19. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 19(1), 10-15 (1995).
20. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2(1), 29-34 (2003).
21. Proesmans M, Balinska-Miskiewicz W, Dupont L et al. Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Respir. J. 27(5), 937-943 (2006).
22. Farrell PM, Govan JR. Pseudomonas serology: confusion, controversy, and challenges. Thorax 61(8), 645-647 (2006).
23. Hayes D Jr, Farrell PM, Li Z, West SE. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr. Pulmonol. 45(1), 55-61 (2010).
24. Kelly NM, Fitzgerald MX, Tempany E, O'Boyle C, Falkiner FR, Keane CT. Does pseudomonas cross-infection occur between cystic-fibrosis patients. Lancet 2(8300), 688-690 (1982).
25. Speert DP, Lawton D, Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J. Pediatr. 101(2), 227-228 (1982).
26. Orsi GB, Mansi A, Tomao P, Chiarini F, Visca P. Lack of association between clinical and environmental isolates of Pseudomonas aeruginosa in hospital wards. J. Hosp. Infect. 27(1), 49-60 (1994).
27. Hoiby N, Rosendal K. Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre. Acta Pathol. Microbiol. Scand. 88(3), 125-131 (1980).
28. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J. Antimicrob. Chemother. 17(4), 505-516 (1986).
29. Hoiby N , Pedersen SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr. Scand. 78(3), 395-404 (1989).
30. Jelsbak L, Johansen HK, Frost AL et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in cystic fibrosis lungs. Infect. Immun. 75(5), 2214-2224 (2007).
31. Cheng K, Smyth RL, Govan JR et al. Spread of p-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348(9028), 639-642 (1996).
32. Edenborough FP, Stone HR, Kelly SJ, Zadik P, Doherty CJ, Govan JR. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. J. Cyst. Fibros. 3(1), 37-44 (2004).
33. Chambers D, Scott F, Bangur R et al. Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis. Eur. Respir. J. 26(4), 651-656 (2005).
34. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59(4), 334-336 (2004).
35. McCallum SJ, Corkill JE, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 358(9281), 558-560 (2001).
36. McCallum SJ, Gallagher MJ, Corkill JE, Hart CA, Ledson MJ, Walshaw MJ. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax 57(6), 559-560 (2002).
37. Mohan K, Fothergill JL, Storrar J, Ledson MJ, Winstanley C, Walshaw MJ. Transmission of Pseudomonas aeruginosa epidemic strain from a patient with cystic fibrosis to a pet cat. Thorax 63(9), 839-840 (2008).
38. Salunkhe P, Smart CH, Morgan JA et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J. BacterioL 187(14), 4908-4920 (2005).
39. Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C. Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol. 7, 45 (2007).
40. Jones AM, Govan JR, Doherty CJ et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 358(9281), 557-558 (2001).
41. Jones AM, Dodd ME, Govan JR et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am. J. Respir. Crit. Care Med. 171(3), 257-260 (2005).
42. Jones AM, Martin L, Bright-Thomas RJ et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur. Respir. J. 22(3), 503-506 (2003).
43. Jones AM, Dodd ME, Doherty CJ, Govan JR, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 57(11), 924-925 (2002).
44. France M, Dodd ME, Govan JR, Doherty CJ, Webb AK, Jones AM. First isolation of Pseudomonas aeruginosa: failure of eradication treatment associated with a clonal strain. Thorax 61(SUPPL. II), ii34-ii34 (2006).
45. Denton M, Kerr KG, Mooney L et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 34(4), 257-261 (2002).
46. Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosastrains in cystic fibrosis patients in England and Wales. J. Med. Microbiol. 53, 609-615 (2004).
47. Armstrong DS, Nixon GM, Carzino R et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am. J. Respir. Crit. Care Med. 166(7), 983-987 (2002).
48. Armstrong DS, Bell SC, Robinson M et al. Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J. Clin. Microbiol. 41(5), 2266-2267 (2003).
49. Robinson P, Carzino R, Armstrong DS, Olinsky A. Pseudomonas cross-infection from cystic fibrosis patients to non-cystic fibrosis patients: implications for inpatient care of respiratory patients. J. Clin. Microbiol. 41(12), 5741 (2003).
50. O'Carroll MR, Syrmis MW, Wainwright CE et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur. Respir. J. 24(1), 101-106 (2004).
51. Griffiths AL, Jamsen K, Carlin JB et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am. J. Respir. Crit. Care Med. 171(9), 1020-1025 (2005).
52. Anthony M, Rose B, Pegler MB et al. Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J. Clin. Microbiol. 40(8), 2772-2778 (2002).
53. Van Daele SG, Franckx H, Verhelst R et al. Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre. Eur. Respir. J. 25(3), 474-481 (2005).
54. Van Daele SG, Vaneechoutte M, de Boeck K et al. Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients. Eur. Respir. J. 28(4), 740-747 (2006).
55. Fluge G, Ojeniyi B, Hoiby N et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin. Microbiol. Infect. 7(5), 238-243 (2001).
56. Adams C, Morris-Quinn M, McConnell F et al. Epidemiology and clinical impact of Pseudomonas aeruginosa infection in cystic fibrosis using AP-PCR fingerprinting. J. Infect. 37(2), 151-158 (1998).
57. Wolz C, Kiosz G, Ogle JW et al. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol. Infect. 102(2), 205-214 (1989).
58. Silbert S, Barth AL, Sader HS. Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients. J. Clin.Microbiol. 39(11), 3976-3981 (2001).
59. Speert DP, Campbell ME, Henry DA et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am. J. Respir. Crit. Care Med. 166(7), 988-993 (2002).
60. Greenberg D, Yagupsky P, Peled N, Goldbart A, Porat N, Tal A. Lack of evidence of transmission of Pseudomonas aeruginosa among cystic fibrosis patients attending health camps at the Dead Sea, Israel. Isr. Med. Assoc. J. 6(9), 531-534 .
61. Agarwal G, Kapil A, Kabra SK, Das BK, Dwivedi SN. Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India. BMC. Microbiol. 5, 43.
62. Grothues D, Koopmann U, von der Hardt H, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J. Clin. Microbiol. 26(10), 1973-1977 (1988).
63. Schmid J, Ling LJ, Leung JL et al. Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics. Eur. Respir. J. 32(6), 1583-1590 (2008).
64. Doring G, Ulrich M, Muller W et al. Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl. Hyg. Umweltmed. 191(5-6), 494-505 (1991).
65. Kerr JR, Martin H, Chadwick MV, Edwards A, Hodson ME, Geddes DM. Evidence against transmission of Pseudomonas aeruginosa by hands and stethoscopes in a cystic fibrosis unit. J. Hosp. Infect. 50(4), 324-326 (2002).
66. Panagea S, Winstanley C, Walshaw MJ, Ledson MJ, Hart CA. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J. Hosp. Infect. 59(2), 102-107 (2005).
67. Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Hosp. Infect. 9(1), 11-21 (1987).
68. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J. Hosp. Infect. 4(1), 31-40 (1983).
69. Humphreys H, Peckham D, Patel P, Knox A. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax 49(11), 1157-1159 (1994).
70. Jones AM, Govan JR, Doherty CJ et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax 58(6), 525-527 (2003).
71. Wainwright CE, France MW, O'Rourke P et al. Cough-generated aerosols of Pseudomonas aeruginosa and other bacteria from cystic fibrosis patients. Thorax 64(11), 926-931 (2009).
72. Cox CS. Physical aspects of bioaerosol particles. In: Bioaerosols Handbook. Cox CS, Wathes CS (Eds). Lewis Publishers, FL, USA, 15-25 (1995).
73. Li Y, Leung G, Tang JW. Role of ventilation in airborne transmission of infectious agents in the built enviroment - a multidisciplinary systematic review. Indoor Air 17, 2-18 (2007).
74. Siegel JD, Rhinehart ED, Jackson M, Chiarello L; The Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. CDC, GA, USA (2007).
75. Tang JW, Li Y, Eames I, Chan PKS, Ridgway GL. Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. J. Hosp. Infect. 64, 100-114 (2006).
76. Duguid JP. The size and duration of air-carriage of respiratory droplets and droplet-nuclei. J. Hygiene 44, 471-480 (1946).
77. Wells WF. On air-borne infection. II. Droplets and droplet nuculei. Am. J. Hygiene 20, 611-618 (1934).
78. Cox CS. Stability of airborne microbes and allergens. In: Bioaerosols Handbook. Cox CS, Wathes CS (Eds). Lewis Publishers, FL, USA, 77-99 (1995).
79. Hess GE. Effects of oxygen on aerosolized Serratia marcescens. Appl. Microbiol. 13(5), 781-787 (1965).
80. Benbough JE. Death mechanisms in airborne Escherichia coli. J. Gen. Microbiol. 47(3), 325-333 (1967).
81. Heidelberg JF, Shahamat M, Levin M et al. Effect of aerosolization on culturability and viability of Gram-negative bacteria. Appl. Environ. Microbiol. 63(9), 3585-3588 (1997).
82. Koller W, Rotter M. [Further investigations on the suitability of gelatine filters for the collection of airborne bacteria]. Zentralbl. Bakteriol. 159(5-6), 546-559 (1974).
83. Crook B. Inertial samplers: biological perspectives. In: Bioaerosols Handbook. Cox CS, Wathes CS (Eds). Lewis Publishers, FL, USA, 247-257 (1995).
84. Macher JM. Positive-hole correction of multiple-jet impactors for collecting viable microorganisms. Am. Ind. Hyg. Assoc. J. 50(11), 561-568 (1989).
85. Somerville MC, Rivers JC. An alternative approach for the correction of bioaerosol data collected with multiple jet impactors. Am. Ind. Hyg. Assoc. J. 55(2), 127-131 (1994).
86. Jensen PA, Todd WF, Davis GN, Scarpino PV. Evaluation of eight bioaerosol samplers challenged with aerosols of free bacteria. Am. Ind. Hyg. Assoc. J. 53(10), 660-667 (1992).
87. Ferroni A, Werkhauser-Bertrand A, Le Bourgeois M et al. Bacterial contamination in the environment of hospitalised children with cystic fibrosis. J. Cyst. Fibros. 7(6), 477-482 (2008).
88. Schaal KP. Medical and microbiological problems arising from airborne infection in hospitals. J. Hosp. Infect. 18(SUPPL. A), 451-459 (1991).
89. Clifton IJ, Fletcher LA, Beggs CB, Denton M, Peckham DG. A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. BMC. Microbiol. 8, 105 (2008).
90. Clifton IJ, Fletcher LA, Beggs CB, Denton M, Conway SP, Peckham DG. An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. J. Cyst. Fibros. 9, 64-68 (2010).
91. Sultan L, Nyka W, Mills C, O'Grady F, Riley RL, Wells WF. Tuberculosis disseminators. A study of the variability of aerial infectivity of tuberculous patients. Am. Rev. Respir. Dis. 82, 358-369 (1960).
92. Li Y, Yu IT, Xu P et al. Predicting super spreading events during the 2003 severe acute respiratory syndrome epidemics in Hong Kong and Singapore. Am. J. Epidemiol. 160(8), 719-728 (2004).
93. Edwards DA, Man JC, Brand P et al. Inhaling to mitigate exhaled bioaerosols. Proc. Natl. Acad. Sci. 101(50), 17383-17388 (2004).
94. Roberts K, Hathway A, Fletcher LA, Beggs CB, Elliott MW, Sleigh PA. Bioaerosol production on a respiratory ward. Indoor Built Environ. 15, 35-40 (2006).
95. Department of Health/Estates and Facilities Division. Health Technical Memorandum 03-101: Specialised Ventilation for Healthcare Premises. Part A - Design and Installation. The Stationary Office, London, UK (2007).
96. Qian H, Li Y, Nielsen PV, Hyldgaard CE, Wong TW, Chwang ATY. Dispersion of exhaled droplet nuclei in a two-bed hospital ward with three different ventilation systems. Indoor Air 16, 111-128 (2006).
97. Cairns G, Kerr KG, Beggs CB et al. Susceptibility of Burkholderia cepacia and other pathogens of importance in cystic fibrosis to u.v. light. Lett. Appl. Microbiol. 32(3), 135-138 (2001).
98. UK CF Trust Control of Infection Group. Pseudomonas aeruginosa infection in people with cystic fibrosis. Suggestions for prevention and infection control. Cystic Fibrosis Trust, Kent, UK (2004).